In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

REGENXBIO is a longtime player in the gene therapy space, but one that’s yet to bring its own therapy to market (in the early ...

San Francisco-based Rad AI, which develops generative AI (GenAI) tools to improve radiology workflows, has raised $60 million ...

The industry is grappling with significant market shifts amidst emerging technologies and changing demands. Companies are now ...

Weber said it is the right time to appoint a successor, given the company's "competitive growth outlook, new product launches ...

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and ...

One explanation for the findings is that ECG data can help to predict the risk of stroke, which can contribute to age-related ...